Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals (ALNY) and maintained a $165 price target.

February 12, 2024 | 5:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald maintains a Neutral rating and a $165 price target on Alnylam Pharmaceuticals.
The reiteration of a Neutral rating and maintenance of a $165 price target by Cantor Fitzgerald suggests that the analyst sees the stock as fairly valued at its current level. This assessment is likely based on the company's current performance and market conditions. The neutral stance indicates that the analyst does not foresee significant short-term price movement in either direction, hence the score of 0. The high relevance score is due to the direct mention and focus on ALNY. The importance is rated at 75, considering that analyst ratings can influence investor sentiment and potentially the stock price, but it's not a guarantee. The confidence level is at 90, reflecting the clear and direct analyst opinion provided.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100